問卷

TPIDB > Search Result

Search Result

篩選

List

84Cases

2024-01-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2020-10-15 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-08-12 - 2027-02-20

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2024-04-01 - 2029-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-03-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-11-30 - 2028-11-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-10-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-10-02 - 2028-01-05

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-05-01 - 2025-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2015-12-10 - 2019-12-31

IIT

Phase II

A PHASE II, OPEN LABEL, MULTICENTER STUDY OF BEVACIZUMAB IN COMBINATION WITH ERLOTINIB VERSUS ERLOTINIB ALONE IN PATIENTS WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES.
  • Condition/Disease

    NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES

  • Test Drug

    (1)Avastin; (2) Erlotinib

Participate Sites
3Sites

Recruiting3Sites